The Asia-Pacific drug discovery market is set to record a CAGR of 7.13% during the forecast period, 2022-2030, and is estimated to reach a revenue of $26849.69 million by 2030.
ASIA-PACIFIC DRUG DISCOVERY MARKET FORECAST 2022-2030
Asia-Pacific Drug Discovery Market by Drug Type (Small Molecule Drug, Biologic Drug) Market by Service (Chemical Services, Drug Metabolism and Pharmacokinetics Services, Biological Services, Other Pharmaceutical Services) Market by End-users (Pharmaceutical Companies, Contract Research Organizations, Research Institutes, Other End-users) Market by Technology (High Throughput Screening, Spectroscopy, Combinatorial Chemistry, Biochips, Pharmacogenomics and Pharmacogenetics, Bioinformatics, Metabolomics, Nanotechnology, Other Technologies) by Geography
The Asia-Pacific drug discovery market is set to record a CAGR of 7.13% during the forecast period, 2022-2030, and is estimated to reach a revenue of $26849.69 million by 2030.
The companies are extending their presence in the region to leverage the large-scale manufacturing capacities and cost-saving abilities of the Asian countries.
To know more about this report, request a free sample copy
The Asia-Pacific drug discovery market growth assessment includes the analysis of Australia & New Zealand, China, Taiwan, Japan, Singapore, Indonesia, South Korea, India, and Rest of Asia-Pacific. In China, the National Medical Products Administration’s (NMPA’s) CDE (Center of Drug Evaluation) oversees the supplementary applications, drug marketing authorization applications, drug production re-registration applications, and drug clinical trial applications. For instance, the China Pharmaceutical Research and Development Center Co Ltd procured the notice of approval for drug clinical trials by the Stata Drug Administration and clinical trials for arteriovenous thrombosis prevention.
In South Korea, medical devices and medicinal products’ clinical trials are governed by the Bioethics and Safety Act and the Pharmaceutical Affairs Act. The final approval for clinical trials is provided by the Ministry of Food and Drug Safety. Also, the trials are to be conducted under GCP guidelines. Additionally, the presence of the Korea Drug Development Fund (KDDF) is a vital part of Korean research and development that contribute to market growth prospects. It is a government-initiated drug development program, and supplemented through collaborations of healthcare-related Korean ministries.
Furthermore, in Singapore, the Health Sciences Authority (HAS) overlooks the regulations of medical devices, innovative therapeutics, drugs, and other health products to fulfill the efficacy, quality, and safety standards. It also contributes to national drug policies’ development.
The segmentation analysis of the Asia-Pacific drug discovery market includes technology, end-user, service, and drug type. The end-user segment is further sub-categorized into research institutes, contract research organizations, pharmaceutical companies, and other end-users.
Research Institutes are part of academia or government established set-ups that specialize in specific areas. These provide services for conducting Phase I, Phase II, Phase III, and Phase IV trials. They play a significant role in the drug discovery market. Also, they collaborate with funding agencies, academic institutions, and pharma industries for developing new drugs, new pharmaceutical technologies, new models, and drug targets. Some market-associated research institutes are Central Drug Institute, India, Purdue Institute for Drug Discovery, the United States, National Institute of Health, the United States, and Institute of Molecular Genetics (IGM), Italy.
A contract research organization offers pharmaceutical research services to biotechnology and pharmaceutical companies. They include both full-service organizations and niche specialty groups. They bring about drug discovery expertise and technological developments. They focus majorly on the R&D and service aspects of the market.
Some of the leading market players in the Asia-Pacific drug discovery market are Bayer AG, AstraZeneca Plc, Charles River Laboratories International Inc, Eli Lilly and Company, etc.
AstraZeneca has a diverse portfolio with vast coverage across rare, specialty care, and primary diseases. The company is focused on discovering, developing, and commercializing prescription medicines in respiratory & immunology, renal & metabolism, and cardiovascular. It has 177 projects in development pipeline.
One of its products, Arimidex®, is indicated for treating hormone receptor-positive advanced breast cancer in postmenopausal women.
Report Synopsis:
| Report Scope | Details |
| Market Forecast Years | 2022-2030 |
| Base Year | 2021 |
| Market Historical Years | 2018-2021 |
| Forecast Units | Revenue ($ Million) |
| Segments Analyzed | Drug Type, Service, End-User, and Technology |
| Countries Analyzed | Australia & New Zealand, China, Taiwan, Japan, Singapore, Indonesia, South Korea, India, and Rest of Asia-Pacific |
| Companies Analyzed | Roche AG, Pfizer Inc, Bayer AG, Evotec SE, Agilent Technologies Inc, Icon Plc, AstraZeneca Plc, Charles River Laboratories International Inc, Novartis AG, Merck & Co Inc, Eli Lilly and Company, IQVIA Holdings Inc, Johnson & Johnson, and GlaxoSmithKline Plc |
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- KEY DRIVERS
- GROWING R&D FOR TACKLING SEVERAL DISEASES
- TECHNOLOGICAL ADVANCEMENTS
- KEY RESTRAINTS
- EXTENSIVE TIME-CONSUMING PROCESS
- HIGHLY REGULATED MARKET
- PROJECT FEASIBILITY AND SUCCESS RATE
- KEY DRIVERS
- KEY ANALYTICS
- IMPACT OF COVID-19 ON DRUG DISCOVERY MARKET
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
- BUYERS POWER
- SUPPLIERS POWER
- SUBSTITUTION
- NEW ENTRANTS
- INDUSTRY RIVALRY
- OPPORTUNITY MATRIX
- DRUG DISCOVERY AND DEVELOPMENT PROCESS
- DRUG DISCOVERY AND DEVELOPMENT
- PRECLINICAL RESEARCH
- CLINICAL RESEARCH
- REGULATORY AUTHORITY REVIEW
- POST MARKET SAFETY MONITORING
- REGULATORY FRAMEWORK
- MARKET BY DRUG TYPE
- SMALL MOLECULE DRUG
- BIOLOGIC DRUG
- MARKET BY SERVICE
- CHEMICAL SERVICES
- DRUG METABOLISM AND PHARMACOKINETICS SERVICES
- BIOLOGICAL SERVICES
- OTHER PHARMACEUTICAL SERVICES
- MARKET BY END-USER
- PHARMACEUTICAL COMPANIES
- CONTRACT RESEARCH ORGANIZATIONS
- RESEARCH INSTITUTES
- OTHER END-USERS
- MARKET BY TECHNOLOGY
- HIGH THROUGHPUT SCREENING
- SPECTROSCOPY
- COMBINATORIAL CHEMISTRY
- BIOCHIPS
- PHARMACOGENOMICS AND PHARMACOGENETICS
- BIOINFORMATICS
- METABOLOMICS
- NANOTECHNOLOGY
- OTHER TECHNOLOGIES
- GEOGRAPHICAL ANALYSIS
- ASIA-PACIFIC
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- INDONESIA
- SINGAPORE
- TAIWAN
- AUSTRALIA & NEW ZEALAND
- REST OF ASIA-PACIFIC
- ASIA-PACIFIC
- COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
- MERGERS & ACQUISITIONS
- PRODUCT LAUNCHES & DEVELOPMENTS
- PARTNERSHIPS & AGREEMENTS
- BUSINESS EXPANSIONS & DIVESTITURES
- COMPANY PROFILES
- AGILENT TECHNOLOGIES INC
- ASTRAZENECA PLC
- BAYER AG
- CHARLES RIVER LABORATORIES INTERNATIONAL INC
- ELI LILLY AND COMPANY
- EVOTEC SE
- GLAXOSMITHKLINE PLC
- ICON PLC
- IQVIA HOLDINGS INC
- JOHNSON & JOHNSON
- MERCK & CO INC
- NOVARTIS AG
- PFIZER INC
- ROCHE AG
- KEY STRATEGIC DEVELOPMENTS
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – ASIA DRUG DISCOVERY
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 4: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 5: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 11: ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 12: ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 13: LEADING PLAYERS OPERATING IN ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET
TABLE 14: LIST OF MERGERS & ACQUISITIONS
TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS
FIGURE 5: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021
FIGURE 6: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2030 (IN $ MILLION)
FIGURE 7: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2030 (IN $ MILLION)
FIGURE 8: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021
FIGURE 9: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
FIGURE 14: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2030 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
FIGURE 17: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)
FIGURE 18: ASIA-PACIFIC DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
FIGURE 19: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2030 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2030 (IN $ MILLION)
FIGURE 21: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2030 (IN $ MILLION)
FIGURE 22: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2030 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2030 (IN $ MILLION)
FIGURE 24: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2030 (IN $ MILLION)
FIGURE 25: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2030 (IN $ MILLION)
FIGURE 26: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2030 (IN $ MILLION)
FIGURE 27: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)
FIGURE 28: ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 29: CHINA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 30: JAPAN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 31: INDIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 32: SOUTH KOREA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 33: INDONESIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 34: SINGAPORE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 35: TAIWAN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 36: AUSTRALIA & NEW ZEALAND DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 37: REST OF ASIA-PACIFIC-PACIFIC DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
- GEOGRAPHICAL ANALYSIS
- ASIA-PACIFIC
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- INDONESIA
- SINGAPORE
- TAIWAN
- AUSTRALIA & NEW ZEALAND
- REST OF ASIA-PACIFIC
- ASIA-PACIFIC
- MARKET BY DRUG TYPE
- SMALL MOLECULE DRUG
- BIOLOGIC DRUG
- MARKET BY SERVICE
- CHEMICAL SERVICES
- DRUG METABOLISM AND PHARMACOKINETICS SERVICES
- BIOLOGICAL SERVICES
- OTHER PHARMACEUTICAL SERVICES
- MARKET BY END-USER
- PHARMACEUTICAL COMPANIES
- CONTRACT RESEARCH ORGANIZATIONS
- RESEARCH INSTITUTES
- OTHER END-USERS
- MARKET BY TECHNOLOGY
- HIGH THROUGHPUT SCREENING
- SPECTROSCOPY
- COMBINATORIAL CHEMISTRY
- BIOCHIPS
- PHARMACOGENOMICS AND PHARMACOGENETICS
- BIOINFORMATICS
- METABOLOMICS
- NANOTECHNOLOGY
- OTHER TECHNOLOGIES
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.